Inflammasome-gasdermin axis in bullous pemphigoid

大疱性类天疱疮的炎症小体-gasdermin轴

基本信息

  • 批准号:
    10382402
  • 负责人:
  • 金额:
    $ 37.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-04-01 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

Project Summary Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease characterized by autoantibodies and an inflammatory infiltrate. BP autoantibodies recognize two hemidesmosomal proteins, BP180 and BP230. Anti-BP180 IgG autoantibodies fix complement and are pathogenic. NC16A, an extracellular domain of BP180, is the primary target of pathogenic autoantibodies. Elevated proinflammatory cytokines TNF-α and IL-1β are present in blister fluids and sera of BP patients. However, the roles of these critical inflammatory mediators and how they are up-regulated in BP remain unknown. Our preliminary results showed that subepidermal blister formation induced by pathogenic antibodies is dependent on IL-1β, a cytokine whose secretion is uniquely dependent upon the inflammasome signaling pathway. We further show that specific inflammasome mutant mice resist the pathology of BP. Therefore, the objective of this proposal is to study the role of inflammasomes in BP using our BP mouse models. Our central hypothesis for this proposal is that BP antibodies trigger an inflammasome cascade starting with the NLRP3 inflammasome (Aim 1), that activates caspase-1 and caspase-14 (Aim 3), culminating in the activation of gasdermin A, which forms the IL-1β secretion pore (Aim 2). The overall goal of this project is to increase our understanding of the innate immunity of BP and how it relates to the functions of innate immune system players in inflammation and autoimmunity. Our preliminary data are promising and strongly support our working hypothesis. Since this proposal integrates both disease mechanistic and preclinical studies, the findings are expected to have a significant impact on the treatment of patients with BP and other skin inflammatory disorders. This grant will also have broader implications to the basic biology of inflammation in the skin. Gasdermin A is a new innate immune gene known to form a pore in the cell membrane, yet its true function in vivo remains a mystery. Because IL-1β is a potent and central inflammatory mediator in skin inflammatory disease, these studies with gasdermin A will have broad impact and will reveal hitherto unimagined aspects of the basic biology of IL-1β secretion from keratinocytes.
项目总结

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Anti-NC16A IgA from Patients with Linear IgA Bullous Dermatosis Induce Neutrophil-Dependent Subepidermal Blistering in Mice.
来自线性 IgA 大疱性皮肤病患者的抗 NC16A IgA 会诱导小鼠中性粒细胞依赖性表皮下水疱。
  • DOI:
    10.1016/j.jid.2023.05.027
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Jing,Ke;Jordan,TylerJM;Li,Ning;Burette,Susan;Yang,Baoqi;Marinkovich,MPeter;Diaz,LuisA;Googe,Paul;Thomas,NancyE;Feng,Suying;Liu,Zhi
  • 通讯作者:
    Liu,Zhi
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zhi Liu其他文献

Zhi Liu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zhi Liu', 18)}}的其他基金

Development of a salt-based nanomedicine for non-muscle invasive bladder cancer
开发用于非肌肉浸润性膀胱癌的盐基纳米药物
  • 批准号:
    10482565
  • 财政年份:
    2022
  • 资助金额:
    $ 37.38万
  • 项目类别:
Development of a radiation-activatable nanoparticle for lung cancer therapy
开发用于肺癌治疗的辐射激活纳米颗粒
  • 批准号:
    10259278
  • 财政年份:
    2021
  • 资助金额:
    $ 37.38万
  • 项目类别:
Inflammasome-gasdermin axis in bullous pemphigoid
大疱性类天疱疮的炎症小体-gasdermin轴
  • 批准号:
    9899921
  • 财政年份:
    2018
  • 资助金额:
    $ 37.38万
  • 项目类别:
Eosinophils in Bullous Pemphigoid
大疱性类天疱疮中的嗜酸性粒细胞
  • 批准号:
    10198769
  • 财政年份:
    2017
  • 资助金额:
    $ 37.38万
  • 项目类别:
Innate Immunity in Bullous Pemphigoid
大疱性类天疱疮的先天免疫
  • 批准号:
    8073124
  • 财政年份:
    2010
  • 资助金额:
    $ 37.38万
  • 项目类别:
Innate Immunity in Bullous Pemphigoid
大疱性类天疱疮的先天免疫
  • 批准号:
    8261445
  • 财政年份:
    2010
  • 资助金额:
    $ 37.38万
  • 项目类别:
Innate Immunity in Bullous Pemphigoid
大疱性类天疱疮的先天免疫
  • 批准号:
    7987670
  • 财政年份:
    2010
  • 资助金额:
    $ 37.38万
  • 项目类别:
Innate Immunity in Bullous Pemphigoid
大疱性类天疱疮的先天免疫
  • 批准号:
    8461644
  • 财政年份:
    2010
  • 资助金额:
    $ 37.38万
  • 项目类别:
The Mechanism of IVIG Action in Pemphigus
IVIG 对天疱疮的作用机制
  • 批准号:
    6890262
  • 财政年份:
    2004
  • 资助金额:
    $ 37.38万
  • 项目类别:
The Mechanism of IVIG Action in Pemphigus
IVIG 对天疱疮的作用机制
  • 批准号:
    6811119
  • 财政年份:
    2004
  • 资助金额:
    $ 37.38万
  • 项目类别:

相似海外基金

Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Operating Grants
Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease
具有异常糖蛋白特异性的致病性自身抗体:自身免疫性疾病治疗靶点的评估
  • 批准号:
    10581585
  • 财政年份:
    2020
  • 资助金额:
    $ 37.38万
  • 项目类别:
Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease
具有异常糖蛋白特异性的致病性自身抗体:自身免疫性疾病治疗靶点的评估
  • 批准号:
    10359090
  • 财政年份:
    2020
  • 资助金额:
    $ 37.38万
  • 项目类别:
Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease
具有异常糖蛋白特异性的致病性自身抗体:自身免疫性疾病治疗靶点的评估
  • 批准号:
    10117072
  • 财政年份:
    2020
  • 资助金额:
    $ 37.38万
  • 项目类别:
Clarify the pathological mechanism for autoimmune encephalitis using recombinant autoantibodies
利用重组自身抗体阐明自身免疫性脑炎的病理机制
  • 批准号:
    19K22548
  • 财政年份:
    2019
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Autoantibodies in patients with autoimmune pancreatitis: its pathophysiological roles and clinical significance
自身免疫性胰腺炎患者自身抗体的病理生理作用及临床意义
  • 批准号:
    18K07958
  • 财政年份:
    2018
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A comprehensive study of antiphospholipid antibodies in autoimmune diseases for which existing autoantibodies are unspecified
现有自身抗体未明确的自身免疫性疾病中抗磷脂抗体的综合研究
  • 批准号:
    16K10031
  • 财政年份:
    2016
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular pathology of autoimmune hemorrhaphilia XIII/13; analysis of anti-factor XIII autoantibodies and elucidation of the mechanism of their generation
自身免疫性血友病XIII/13的分子病理学;
  • 批准号:
    16K09820
  • 财政年份:
    2016
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The study of anti-endothelial cell autoantibodies in patients with autoimmune encephalitis
自身免疫性脑炎患者抗内皮细胞自身抗体的研究
  • 批准号:
    15K09337
  • 财政年份:
    2015
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Pathogenesis of Autoimmune Hemorrhaphilia XIII/13: Analysis of Anti-FXIII/13 Autoantibodies and Elucidation of Their Generation Mechanisms
自身免疫性血友病XIII/13的发病机制:抗FXIII/13自身抗体的分析及其产生机制的阐明
  • 批准号:
    25461444
  • 财政年份:
    2013
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了